GeneDx (NASDAQ:WGS) Issues Quarterly Earnings Results

GeneDx (NASDAQ:WGS) issued its quarterly earnings data on Monday. The company reported $0.01 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.20, FiscalAI reports. The company had revenue of $114.44 million during the quarter, compared to analysts’ expectations of $111.01 million. GeneDx had a positive return on equity of 9.15% and a negative net margin of 17.58%.

Here are the key takeaways from GeneDx’s conference call:

• Record testing volume and return to profitability: GeneDx processed 30,785 exome and genome tests in Q2, up 32% year over year, generated $114.4 million in revenue, and posted $0.4 million in adjusted net income. The company reaffirmed full-year revenue guidance of $475 million–$490 million and expects to remain profitable for 2026.
• Coverage expansion creates a potential reimbursement tailwind: Commercial genome coverage increased from 47% to 87% of covered lives, driven largely by Carelon, while 39 states now cover exome or genome testing through Medicaid. Management expects the revenue impact to begin emerging in Q4 2026 and become more significant in 2027 as coverage translates into claims payments.
• Revenue cycle management is the primary growth opportunity but remains early: The outpatient genome collection rate was approximately 32%, with exome rates described as comparable, versus management’s long-term target of roughly 70%. Payer-specific workflows, improved prior authorization and denial management, and technology investments are being implemented, but collection rates are expected to remain roughly flat in Q3.
• Demand is broadening beyond GeneDx’s core markets: The company maintained about 80% share among geneticists and reached roughly 50% among pediatric neurologists, while General Pediatrics and prenatal testing showed early growth. New sales representatives, corporate pediatric accounts, and the planned “one-minute” ordering tool are expected to support further adoption.
• Liquidity and operating efficiency improved: GeneDx completed its planned $25 million in annual cost reductions, expanded its debt facility by $50 million, and received a strategic equity investment from Blackstone Life Sciences, bringing pro forma liquidity to approximately $188 million. Management also cited gross-margin improvement to 70%, additional AI-driven productivity opportunities, and a return to cash-flow generation expected in Q4.

GeneDx Stock Performance

GeneDx stock traded up $2.75 during trading hours on Monday, reaching $67.86. 1,700,330 shares of the stock were exchanged, compared to its average volume of 999,248. GeneDx has a 52-week low of $32.21 and a 52-week high of $170.87. The stock has a market cap of $2.01 billion, a P/E ratio of -25.32 and a beta of 1.92. The company has a debt-to-equity ratio of 0.38, a quick ratio of 2.95 and a current ratio of 3.09. The firm’s 50 day moving average is $60.67 and its 200 day moving average is $69.59.

Insider Activity

In other news, Director Keith A. Meister acquired 46,273 shares of GeneDx stock in a transaction that occurred on Friday, May 15th. The stock was purchased at an average price of $38.91 per share, for a total transaction of $1,800,482.43. Following the completion of the transaction, the director directly owned 4,784,570 shares in the company, valued at approximately $186,167,618.70. This trade represents a 0.98% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Casdin Capital, Llc acquired 50,000 shares of the stock in a transaction on Friday, June 5th. The stock was acquired at an average cost of $52.86 per share, for a total transaction of $2,643,000.00. Following the acquisition, the director directly owned 3,707,164 shares in the company, valued at $195,960,689.04. This represents a 1.37% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders acquired 2,256,420 shares of company stock worth $93,144,340 and sold 19,135 shares worth $1,128,499. Corporate insiders own 25.17% of the company’s stock.

Institutional Trading of GeneDx

Several hedge funds have recently modified their holdings of WGS. Franklin Resources Inc. grew its holdings in shares of GeneDx by 101.9% in the 3rd quarter. Franklin Resources Inc. now owns 681,381 shares of the company’s stock worth $73,412,000 after acquiring an additional 343,954 shares during the period. Invesco Ltd. raised its holdings in GeneDx by 59.2% during the fourth quarter. Invesco Ltd. now owns 786,466 shares of the company’s stock worth $102,288,000 after purchasing an additional 292,394 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in GeneDx by 717.3% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 258,745 shares of the company’s stock worth $33,652,000 after purchasing an additional 227,088 shares during the last quarter. ARK Investment Management LLC boosted its position in GeneDx by 35.3% during the fourth quarter. ARK Investment Management LLC now owns 604,561 shares of the company’s stock worth $78,629,000 after purchasing an additional 157,582 shares in the last quarter. Finally, Ameriprise Financial Inc. grew its holdings in GeneDx by 76.2% in the second quarter. Ameriprise Financial Inc. now owns 255,931 shares of the company’s stock valued at $23,625,000 after purchasing an additional 110,684 shares during the last quarter. 61.72% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the stock. Wells Fargo & Company reissued an “overweight” rating and set a $75.00 price objective (down from $155.00) on shares of GeneDx in a research report on Tuesday, May 5th. Guggenheim reiterated a “buy” rating and set a $74.00 target price (up from $70.00) on shares of GeneDx in a research note on Monday, June 29th. Wall Street Zen lowered GeneDx from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. BTIG Research dropped their price target on GeneDx from $170.00 to $90.00 and set a “buy” rating on the stock in a research report on Tuesday, May 5th. Finally, Canaccord Genuity Group set a $75.00 price objective on GeneDx and gave the company a “buy” rating in a research note on Tuesday, May 5th. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, GeneDx currently has a consensus rating of “Moderate Buy” and a consensus price target of $87.43.

Trending Headlines about GeneDx

Here are the key news stories impacting GeneDx this week:

• Neutral Sentiment: GeneDx reported its second-quarter 2026 financial and operating results on August 3. The release is the primary near-term catalyst for the stock, although the supplied article details do not include revenue, earnings, cash-flow, or guidance figures needed to determine whether the results exceeded expectations. GeneDx Reports Second Quarter 2026 Financial Results
• Negative Sentiment: Several investor-rights law firms publicized a securities class action against GeneDx and certain officers, alleging violations of federal securities laws for investors who acquired shares between April 16, 2025, and May 4, 2026. The announcements primarily remind investors of the August 3 deadline to seek lead-plaintiff status; the allegations have not been proven, but the litigation creates potential legal costs, reputational risk, and uncertainty for shareholders. GeneDx Class Action Announcement Faruqi GeneDx Class Action Deadline

About GeneDx

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.